EP2621931A4 - Tetracyclic indole derivatives for treating hepatitis c virus infection - Google Patents

Tetracyclic indole derivatives for treating hepatitis c virus infection

Info

Publication number
EP2621931A4
EP2621931A4 EP11827912.4A EP11827912A EP2621931A4 EP 2621931 A4 EP2621931 A4 EP 2621931A4 EP 11827912 A EP11827912 A EP 11827912A EP 2621931 A4 EP2621931 A4 EP 2621931A4
Authority
EP
European Patent Office
Prior art keywords
virus infection
indole derivatives
treating hepatitis
tetracyclic indole
tetracyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11827912.4A
Other languages
German (de)
French (fr)
Other versions
EP2621931A1 (en
Inventor
Joseph A Kozlowski
Stuart B Rosenblum
Craig A Coburn
Bandarpalle B Shankar
G Nair Anilkumar
Lei Chen
Michael P Dwyer
Yueheng Jiang
Kartik M Keertikar
Brian J Lavey
Oleg B Selyutin
Ling Tong
Michael Wong
De-Yi Yang
Wensheng Yu
Guowei Zhou
Hao Wu
Bin Hu
Bin Zhong
Fei Sun
Tao Ji
Changmao Shen
Razia Rizvi
Qingbei Zeng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2010/077493 external-priority patent/WO2012040923A1/en
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of EP2621931A1 publication Critical patent/EP2621931A1/en
Publication of EP2621931A4 publication Critical patent/EP2621931A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
EP11827912.4A 2010-09-29 2011-09-28 Tetracyclic indole derivatives for treating hepatitis c virus infection Withdrawn EP2621931A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2010/077493 WO2012040923A1 (en) 2010-09-29 2010-09-29 Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases
US201061426724P 2010-12-23 2010-12-23
PCT/CN2011/001638 WO2012041014A1 (en) 2010-09-29 2011-09-28 Tetracyclic indole derivatives for treating hepatitis c virus infection

Publications (2)

Publication Number Publication Date
EP2621931A1 EP2621931A1 (en) 2013-08-07
EP2621931A4 true EP2621931A4 (en) 2014-03-19

Family

ID=45891857

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11827912.4A Withdrawn EP2621931A4 (en) 2010-09-29 2011-09-28 Tetracyclic indole derivatives for treating hepatitis c virus infection

Country Status (8)

Country Link
EP (1) EP2621931A4 (en)
JP (1) JP2013538831A (en)
KR (1) KR20140001879A (en)
AU (1) AU2011307953B2 (en)
BR (1) BR112013007696A2 (en)
CA (1) CA2811662A1 (en)
MX (1) MX2013003631A (en)
WO (1) WO2012041014A1 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190127365A1 (en) 2017-11-01 2019-05-02 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus replication
AP3622A (en) 2009-05-13 2016-03-02 Gilead Sciences Inc Antiviral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
DK2455376T3 (en) 2009-06-11 2015-03-02 Abbvie Bahamas Ltd Heterocyclic compounds as inhibitors of hepatitis C virus (HCV)
WO2011009084A2 (en) 2009-07-16 2011-01-20 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of flavivirus infections
CA2794145A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
CA2809261A1 (en) 2010-08-26 2012-03-01 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis c virus
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
AU2012283609B2 (en) 2011-07-09 2016-09-29 Sunshine Lake Pharma Co., Ltd. Spiro compounds as hepatitis C virus inhibitors
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
MX354958B (en) 2011-09-16 2018-03-27 Gilead Pharmasset Llc Methods for treating hcv.
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9073943B2 (en) 2012-02-10 2015-07-07 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
TWI610916B (en) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceuticals applications thereof
CN103848821B (en) 2012-11-29 2016-10-12 广东东阳光药业有限公司 Spiro-compound, pharmaceutical composition and their purposes as hepatitis c inhibitor
WO2014082380A1 (en) 2012-11-29 2014-06-05 Sunshine Lake Pharma Co., Ltd. Fused ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
WO2014110688A1 (en) * 2013-01-16 2014-07-24 Merck Sharp & Dohme Corp. Thiophene- sub stitued tetracyclic compounds and methods of use thereof for the treatment of viral diseases
WO2014110687A1 (en) * 2013-01-16 2014-07-24 Merck Sharp & Dohme Corp. Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
PL2950786T3 (en) 2013-01-31 2020-05-18 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
WO2014121417A1 (en) * 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121418A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
CN104230946B (en) * 2013-06-06 2017-03-08 爱博新药研发(上海)有限公司 The compound of suppression hepatitis C virus, pharmaceutical composition and its application
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
EP3021845A1 (en) 2013-07-17 2016-05-25 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of hcv
PL3038601T3 (en) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US9725464B2 (en) * 2013-10-30 2017-08-08 Merck Sharp & Dohme Corp. Process for preparing tetracyclic heterocycle compounds
WO2015089810A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
CN104803989B (en) 2014-01-23 2017-12-22 广东东阳光药业有限公司 Application as the endocyclic compound of hepatitis c inhibitor and its in medicine
US20170166586A1 (en) 2014-07-11 2017-06-15 Hongming Li Process for making tetracyclic heterocycle compounds
WO2016196932A1 (en) * 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Process for preparing substituted tetracyclic heterocycle compounds
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN108290904B (en) * 2015-12-10 2020-10-09 正大天晴药业集团股份有限公司 Deuterium modified elbasvir derivatives, pharmaceutical compositions containing the same and uses thereof
WO2017181947A1 (en) * 2016-04-20 2017-10-26 深圳市塔吉瑞生物医药有限公司 Substituted diamine carbamate, and pharmaceutical composition and application thereof
WO2018032467A1 (en) * 2016-08-18 2018-02-22 Merck Sharp & Dohme Corp. Chromane-substitued tetracyclic compounds and uses thereof for treatment of viral diseases
WO2018032468A1 (en) 2016-08-18 2018-02-22 Merck Sharp & Dohme Corp. Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
RU2650610C1 (en) 2017-02-28 2018-04-16 Васильевич Иващенко Александр Antiviral composition and method of its application
RU2659388C1 (en) 2017-02-28 2018-07-02 Васильевич Иващенко Александр Nucleotides including n-[(s)-1-cyclobutoxycarbonyl]phosphoramidate fragment, their analogs and their application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049593A1 (en) * 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US20080299075A1 (en) * 2006-08-11 2008-12-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2010111483A1 (en) * 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus replication

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704992B2 (en) * 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010065681A1 (en) * 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
CA2746004C (en) * 2008-12-03 2017-06-06 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049593A1 (en) * 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US20080299075A1 (en) * 2006-08-11 2008-12-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2010111483A1 (en) * 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus replication

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2012041014A1 *

Also Published As

Publication number Publication date
CA2811662A1 (en) 2012-04-05
AU2011307953B2 (en) 2014-07-31
WO2012041014A1 (en) 2012-04-05
BR112013007696A2 (en) 2019-09-24
JP2013538831A (en) 2013-10-17
EP2621931A1 (en) 2013-08-07
AU2011307953A1 (en) 2013-04-04
MX2013003631A (en) 2013-10-01
KR20140001879A (en) 2014-01-07

Similar Documents

Publication Publication Date Title
EP2621931A4 (en) Tetracyclic indole derivatives for treating hepatitis c virus infection
EP2621932A4 (en) Tetracyclic heterocycle compounds for treating hepatitis c viral infection
HUS1500019I1 (en) Hepatitis C virus inhibitors
IL221033A0 (en) Hepatitis c virus inhibitors
IL219516A0 (en) Hepatitis c virus inhibitors
HK1163067A1 (en) Hepatitis c virus inhibitors
IL219517A0 (en) Hepatitis c virus inhibitors
EP2575819A4 (en) Hepatitis c virus inhibitors
ZA201107095B (en) Hepatitis c virus inhibitors
ZA201106795B (en) Hepatitis c virus inhibitors
ZA201106669B (en) Hepatitis c virus inhibitors
ZA201106629B (en) Hepatitis c virus inhibitors
EP2475254A4 (en) Hepatitis c virus inhibitors
EP2475256A4 (en) Hepatitis c virus inhibitors
EP2491033A4 (en) Azaindazoles to treat flaviviridae virus infection
HRP20171892T1 (en) Macrocyclic indole derivatives useful as hepatitis c virus inhibitors
EP2429568A4 (en) Macrocyclic compounds as hepatitis c virus inhibitors
IL224298A (en) Hepatitis c virus inhibitors
ZA201205547B (en) Therapies for treating hepatitis c virus infection
EP2603080A4 (en) Hepatitis c virus inhibitors
HK1208364A1 (en) Method for treating hepatitis c virus infection using quercetin- containing compositions
EP2341924A4 (en) Methods of treating hepatitis c virus infection
ZA201300992B (en) Combination therapy for treating hcv infection
PL2331554T3 (en) Macrocyclic indole derivatives useful as hepatitis c virus inhibitors
DK2403856T3 (en) METHYLENDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED FOR CANCER TREATMENT

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130429

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20140213

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/12 20060101ALN20140207BHEP

Ipc: C07D 487/04 20060101ALI20140207BHEP

Ipc: C07D 471/04 20060101ALI20140207BHEP

Ipc: C07D 498/04 20060101AFI20140207BHEP

Ipc: A61K 31/5365 20060101ALI20140207BHEP

Ipc: A61K 31/4985 20060101ALI20140207BHEP

Ipc: A61K 31/437 20060101ALI20140207BHEP

Ipc: A61P 31/14 20060101ALI20140207BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20150126